Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.993 USD | -2.65% | -0.45% | -10.50% |
Business Summary
Number of employees: 72
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Therapeutic Products
100.0
%
| 15 | 100.0 % | 9 | 100.0 % | -39.16% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 15 | 100.0 % | 9 | 100.0 % | -39.16% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Brian Culley
CEO | Chief Executive Officer | 53 | 18-09-16 |
Jill Howe
DFI | Director of Finance/CFO | 48 | 22-11-13 |
Chief Operating Officer | - | 09-12-31 | |
Gary Hogge
CTO | Chief Tech/Sci/R&D Officer | 56 | 18-01-31 |
Ioana C. Hone
IRC | Investor Relations Contact | - | - |
George Samuel
LAW | General Counsel | 43 | 21-08-31 |
Derek Kelaita
PRN | Corporate Officer/Principal | - | 19-07-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Neal Bradsher
BRD | Director/Board Member | 58 | 09-06-30 |
Brian Culley
CEO | Chief Executive Officer | 53 | 18-09-16 |
Deborah Andrews
BRD | Director/Board Member | 66 | 14-04-10 |
Don Bailey
BRD | Director/Board Member | 78 | 20-02-29 |
Angus Russell
BRD | Director/Board Member | 68 | 14-12-08 |
Michael Mulroy
CHM | Chairman | 58 | 14-10-03 |
Director/Board Member | 67 | 21-05-03 | |
Dipti Amin
BRD | Director/Board Member | 60 | 21-04-19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 188,823,975 | 188,001,177 ( 99.56 %) | 0 | 99.56 % |
Company contact information
Lineage Cell Therapeutics, Inc.
2173 Salk Avenue Suite 200
92008-7354, Carlsbad
+442 287 8990
http://www.lineagecell.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.50% | 193M | |
+45.21% | 56.65B | |
-7.11% | 39.44B | |
+39.19% | 39.03B | |
-11.17% | 26.86B | |
+12.31% | 26.75B | |
-21.60% | 19.03B | |
+1.40% | 12.28B | |
+24.19% | 12.26B | |
+27.52% | 12.04B |
- Stock Market
- Equities
- LCTX Stock
- Company Lineage Cell Therapeutics, Inc.